Trioson
Generic Name
Fluticasone Furoate, Vilanterol, Umeclidinium
Manufacturer
Hypothetical Pharma Co.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| trioson 200 mcg inhaler | ৳ 900.00 | N/A |
Description
Overview of the medicine
Trioson-200-mcg-inhaler is a triple combination inhaler containing an inhaled corticosteroid (fluticasone furoate), a long-acting beta-2 adrenergic agonist (vilanterol), and a long-acting muscarinic antagonist (umeclidinium). It is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Uses & Indications
Dosage
Adults
One inhalation once daily.
Elderly
No dose adjustment required.
Renal_impairment
No dose adjustment required.
How to Take
Administer orally via inhalation once daily, preferably at the same time each day. Do not use to treat acute bronchospasm.
Mechanism of Action
Fluticasone furoate is an anti-inflammatory corticosteroid. Vilanterol is a selective, long-acting beta2-adrenergic agonist that causes bronchodilation. Umeclidinium is a long-acting muscarinic antagonist that also causes bronchodilation. Together, they reduce airway inflammation and open up the airways, improving breathing.
Pharmacokinetics
Onset
Bronchodilatory effect within minutes (Vilanterol), full anti-inflammatory effect develops over days/weeks (Fluticasone Furoate).
Excretion
Mainly fecal for Fluticasone Furoate and Umeclidinium, both renal and fecal for Vilanterol.
Half life
Fluticasone Furoate: ~24 hours; Vilanterol: ~11 hours; Umeclidinium: ~19 hours.
Absorption
Rapidly absorbed after inhalation; systemic bioavailability is low due to extensive first-pass metabolism.
Metabolism
Primarily hepatic via CYP3A4 (Fluticasone Furoate, Vilanterol) and CYP2D6 (Umeclidinium).
Side Effects
Contraindications
- Severe hypersensitivity to milk proteins or any components of Trioson-200-mcg-inhaler
- Primary treatment of status asthmaticus or other acute episodes of COPD where intensive measures are required
Drug Interactions
Beta-blockers
May blunt the bronchodilatory effect of vilanterol and cause severe bronchospasm.
Anticholinergics (e.g., Ipratropium)
Avoid coadministration with other anticholinergic-containing drugs due to potential for additive effects.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)
May increase systemic exposure to fluticasone furoate and vilanterol, increasing risk of systemic corticosteroid effects and cardiovascular effects.
Storage
Store at room temperature (below 30°C), away from moisture and direct heat. Keep out of reach of children.
Overdose
Symptoms may include tachycardia, tremor, headache, and hypertension (due to LABA) and systemic corticosteroid effects (due to ICS). Management is symptomatic and supportive.
Pregnancy & Lactation
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when administered to a nursing woman.
Side Effects
Contraindications
- Severe hypersensitivity to milk proteins or any components of Trioson-200-mcg-inhaler
- Primary treatment of status asthmaticus or other acute episodes of COPD where intensive measures are required
Drug Interactions
Beta-blockers
May blunt the bronchodilatory effect of vilanterol and cause severe bronchospasm.
Anticholinergics (e.g., Ipratropium)
Avoid coadministration with other anticholinergic-containing drugs due to potential for additive effects.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)
May increase systemic exposure to fluticasone furoate and vilanterol, increasing risk of systemic corticosteroid effects and cardiovascular effects.
Storage
Store at room temperature (below 30°C), away from moisture and direct heat. Keep out of reach of children.
Overdose
Symptoms may include tachycardia, tremor, headache, and hypertension (due to LABA) and systemic corticosteroid effects (due to ICS). Management is symptomatic and supportive.
Pregnancy & Lactation
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 months from manufacturing date when stored correctly.
Availability
Pharmacies and Hospitals
Approval Status
Approved by major regulatory bodies (e.g., FDA)
Patent Status
Patented (active for key components)
Clinical Trials
Extensive clinical trials (e.g., FULFIL, IMPACT) have demonstrated efficacy and safety in COPD patients.
Lab Monitoring
- Monitor for signs of pneumonia (especially in COPD patients)
- Monitor for systemic corticosteroid effects (e.g., adrenal suppression, bone density changes)
- Monitor for cardiovascular effects (e.g., ECG changes, blood pressure)
Doctor Notes
- Emphasize correct inhaler technique to patients.
- Regular follow-up is essential to monitor for adverse effects and disease progression.
- Not for acute relief; ensure patient has a rescue inhaler.
Patient Guidelines
- Use regularly as prescribed, even when feeling well.
- Rinse mouth with water after each use to reduce the risk of oral candidiasis.
- Do not use to relieve sudden breathing problems; use a rescue inhaler for acute symptoms.
Missed Dose Advice
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not take two doses at once.
Driving Precautions
May cause dizziness or blurred vision in some individuals. Exercise caution when driving or operating machinery if affected.
Lifestyle Advice
- Avoid smoking.
- Maintain a healthy lifestyle and diet.
- Regular exercise (as advised by physician).
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Trioson Brand
Other medicines available under the same brand name
